<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:media="http://search.yahoo.com/mrss/" version="2.0">
<channel>
<title><![CDATA[RSS for GlaxoSmithKline]]></title>
<description><![CDATA[GlaxoSmithKline news and videos. Watch GlaxoSmithKline video clips and read news updates on GlaxoSmithKline on FOXBusiness.com.]]></description>
<link><![CDATA[http://www.foxbusiness.com/search-results/]]></link>
<atom:link xmlns:atom="http://www.w3.org/2005/Atom" type="application/rss+xml" rel="self" href="http://www.foxbusiness.com/search-results/urss?pageid=217668"/>
<item>
<title><![CDATA[Elan rejects Royalty's $6.4 billion raised offer]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/23/elan-rejects-royalty-64-billion-raised-offer/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/23/elan-rejects-royalty-64-billion-raised-offer/</guid>
<pubDate><![CDATA[Thu, 23 May 2013 13:36:15 EDT]]></pubDate>
<description><![CDATA[Elan rejected Royalty Pharma's increased $6.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Pfizer takes its shot at a vaccine for evasive superbug]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/23/pfizer-takes-its-shot-at-vaccine-for-evasive-superbug/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/23/pfizer-takes-its-shot-at-vaccine-for-evasive-superbug/</guid>
<pubDate><![CDATA[Thu, 23 May 2013 01:20:51 EDT]]></pubDate>
<description><![CDATA[Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis vaccine Prevnar 13 for Pfizer.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[U.S. Gives Glaxo Up To $200 Million for Antibiotic Research]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/22/us-gives-glaxo-up-to-200-million-for-antibiotic-research/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/22/us-gives-glaxo-up-to-200-million-for-antibiotic-research/</guid>
<pubDate><![CDATA[Wed, 22 May 2013 15:35:03 EDT]]></pubDate>
<description><![CDATA[Concerned about the need to fight antibiotic resistance and possible bioterrorist attacks, the U.S. government will give drug maker GlaxoSmithKline PLC (GSK, GSK.LN) up to $200 million over the next five years to help fund research into new antibiotics.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[GlaxoSmithKline Awarded Up to $200 Million by US to Develop New Antibiotics]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/22/glaxosmithkline-awarded-up-to-200-million-by-us-to-develop-new-antibiotics/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/22/glaxosmithkline-awarded-up-to-200-million-by-us-to-develop-new-antibiotics/</guid>
<pubDate><![CDATA[Wed, 22 May 2013 07:25:15 EDT]]></pubDate>
<description><![CDATA[Drug group GlaxoSmithKline PLC (GSK.LN) said Wednesday that it has been awarded up to $200 million by the U.S. government to develop new antibiotics.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[GlaxoSmithKline Shuts Australia Packaging Site]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/22/glaxosmithkline-shuts-australia-packaging-site/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/22/glaxosmithkline-shuts-australia-packaging-site/</guid>
<pubDate><![CDATA[Wed, 22 May 2013 00:45:04 EDT]]></pubDate>
<description><![CDATA[GlaxoSmithKline PLC (GSK) said it would close an Australian tablet-packaging facility and lay off 120 workers, joining a string of manufacturers that have shut factories, slashed jobs and relocated production overseas in response to high labor costs and a strong local currency.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[GlaxoSmithKline Shuts Australian Tablet-Packing Site]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/21/glaxosmithkline-shuts-australian-tablet-packing-site/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/21/glaxosmithkline-shuts-australian-tablet-packing-site/</guid>
<pubDate><![CDATA[Tue, 21 May 2013 19:22:42 EDT]]></pubDate>
<description><![CDATA[GlaxoSmithKline PLC (GSK) said Wednesday it was closing an Australian tablet-packaging plant, leading to 120 job losses.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[C.R. Bard to Pay $48.3 Million to Settle Kickback Case -DOJ]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/13/cr-bard-to-pay-483-million-to-settle-kickback-case-doj/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/13/cr-bard-to-pay-483-million-to-settle-kickback-case-doj/</guid>
<pubDate><![CDATA[Mon, 13 May 2013 19:22:29 EDT]]></pubDate>
<description><![CDATA[C.R. Bard Inc. (BCR) has agreed to pay around $48.3 million to resolve whistleblower allegations that it gave kickbacks to doctors and other customers to buy the company's radiation treatment for prostate cancer, the Justice Department said.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[LONDON MARKETS: GSK, Shell Lead U.K. Stocks To 8th Day Of Gains]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/13/london-markets-gsk-shell-lead-uk-stocks-to-8th-day-gains/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/13/london-markets-gsk-shell-lead-uk-stocks-to-8th-day-gains/</guid>
<pubDate><![CDATA[Mon, 13 May 2013 12:07:56 EDT]]></pubDate>
<description><![CDATA[U.K. stocks managed to eke out an eighth straight day of gains on Monday, as Royal Dutch Shell PLC rose after announcing a share buyback and GlaxoSmithKline PLC climbed after a new drug approval.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[EUROPE MARKETS: Europe Stocks Retreat From 2013 High]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/13/europe-markets-europe-stocks-retreat-from-2013-high/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/13/europe-markets-europe-stocks-retreat-from-2013-high/</guid>
<pubDate><![CDATA[Mon, 13 May 2013 12:04:32 EDT]]></pubDate>
<description><![CDATA[European stock markets retreated from a 2013 high on Monday after a mixed bag of Chinese data highlighted growth concerns in the world's second largest economy.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Late payment costs European companies 350 billion euros]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/13/late-payment-costs-european-companies-350-billion-euros/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/13/late-payment-costs-european-companies-350-billion-euros/</guid>
<pubDate><![CDATA[Mon, 13 May 2013 09:01:42 EDT]]></pubDate>
<description><![CDATA[European companies lost 350 billion euros ($450 billion) last year due to late or unpaid bills, underlining fears that small businesses expected to drive economic recovery are faltering in a prolonged recession.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Elan's $1 billion drug royalty deal aids bid defense]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/13/elan-1-billion-drug-royalty-deal-aids-bid-defense/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/13/elan-1-billion-drug-royalty-deal-aids-bid-defense/</guid>
<pubDate><![CDATA[Mon, 13 May 2013 08:16:52 EDT]]></pubDate>
<description><![CDATA[Irish drugmaker Elan Corporation has agreed a $1 billion royalties deal that could soothe concerns about its potentially risky acquisition strategy and fend off a takeover bid from Royalty Pharma.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Elan Signs $1 Billion Drug Deal]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/13/elan-signs-1-billion-drug-deal/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/13/elan-signs-1-billion-drug-deal/</guid>
<pubDate><![CDATA[Mon, 13 May 2013 05:45:05 EDT]]></pubDate>
<description><![CDATA[Elan Corp. (ELN) Monday said it had reached a $1 billion deal with Theravance Inc. (THRX) for a share in the royalty stream of four respiratory drug programs, as the Irish company fends off approaches from pharmaceutical investor Royalty Pharma.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Elan, Theravance Enter Into $1.0 Billion Royalty Participation Pact]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/13/elan-theravance-enter-into-10-billion-royalty-participation-pact/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/13/elan-theravance-enter-into-10-billion-royalty-participation-pact/</guid>
<pubDate><![CDATA[Mon, 13 May 2013 02:34:03 EDT]]></pubDate>
<description><![CDATA[Elan Corporation PLC (ELN) said Monday it and Theravance Inc. (THRX) have entered into a royalty participation agreement wherein Elan will buy a 21% interest in potential future royalty payments related to four respiratory programs partnered with GlaxoSmithKline PLC (GSK) for $1 billion.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[FDA Approves GlaxoSmithKline's Breo Ellipta to Treat Lung Disease]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/10/fda-approves-glaxosmithkline-breo-ellipta-to-treat-lung-disease/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/10/fda-approves-glaxosmithkline-breo-ellipta-to-treat-lung-disease/</guid>
<pubDate><![CDATA[Fri, 10 May 2013 14:33:45 EDT]]></pubDate>
<description><![CDATA[The U.S. Food and Drug Administration Friday approved a new drug that will be marketed by GlaxoSmithKline PLC (GSK, GSK.LN) to treat chronic obstructive pulmonary disease, or COPD.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[GSK, Theravance See Breo Ellipta Available in 3Q13 After FDA Approval]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/10/gsk-theravance-see-breo-ellipta-available-in-3q13-after-fda-approval/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/10/gsk-theravance-see-breo-ellipta-available-in-3q13-after-fda-approval/</guid>
<pubDate><![CDATA[Fri, 10 May 2013 12:27:11 EDT]]></pubDate>
<description><![CDATA[GlaxoSmithKline PLC (GSK.LN) and Theravance, Inc. (THRX) Friday said the U.S. Food and Drug Administration, or FDA, approved Breo Ellipta as an inhaled treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, and said it expects the treatment to be available in the U.S. in the third quarter of this year.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[FDA OKs GlaxoSmithKline Drug to Treat Lung Disease]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/10/fda-oks-glaxosmithkline-drug-to-treat-lung-disease/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/10/fda-oks-glaxosmithkline-drug-to-treat-lung-disease/</guid>
<pubDate><![CDATA[Fri, 10 May 2013 12:15:02 EDT]]></pubDate>
<description><![CDATA[The U.S. Food and Drug Administration Friday approved a new drug that will be marketed by GlaxoSmithKline PLC (GSK, GSK.LN) to treat chronic obstructive pulmonary disease, or COPD.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Companies Serving Consumers in India Are M&A Targets]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/01/companies-serving-consumers-in-india-are-ma-targets/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/01/companies-serving-consumers-in-india-are-ma-targets/</guid>
<pubDate><![CDATA[Wed, 01 May 2013 14:22:13 EDT]]></pubDate>
<description><![CDATA[Companies serving Indian consumers are attracting billions of dollars in foreign investment even as deals in other parts of the country's economy have nearly stalled.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[GlaxoSmithKline Gets 3 Month Extension to Trametinib PDUFA Goal Date]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/01/glaxosmithkline-gets-3-month-extension-to-trametinib-pdufa-goal-date/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/01/glaxosmithkline-gets-3-month-extension-to-trametinib-pdufa-goal-date/</guid>
<pubDate><![CDATA[Wed, 01 May 2013 07:55:14 EDT]]></pubDate>
<description><![CDATA[Research-based pharmaceutical and healthcare company GlaxoSmithKline PLC (GSK.LN) said Wednesday the U.S. Prescription Drug User Fee Act, or PDUFA, goal date for trametinib, its MEK inhibitor, has been extended by three months to Sept. 3.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[GlaxoSmithKline Files Drug Application for UMEC in US]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/30/glaxosmithkline-files-drug-application-for-umec-in-us/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/30/glaxosmithkline-files-drug-application-for-umec-in-us/</guid>
<pubDate><![CDATA[Tue, 30 Apr 2013 08:19:30 EDT]]></pubDate>
<description><![CDATA[Pharmaceutical company GlaxoSmithKline PLC (GSK.LN) Tuesday announced the submission of a regulatory application in the U.S. for the investigational once-daily medicine, umeclidinium bromide (UMEC), for patients with chronic obstructive pulmonary disease (COPD).]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Unilever to raise stake in Indian unit in $5.4 billion offer]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/30/unilever-to-raise-stake-in-indian-unit-in-54-billion-offer/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/30/unilever-to-raise-stake-in-indian-unit-in-54-billion-offer/</guid>
<pubDate><![CDATA[Tue, 30 Apr 2013 02:14:24 EDT]]></pubDate>
<description><![CDATA[Anglo-Dutch consumer goods giant Unilever Plc will pay as much as $5.]]></description>
<media:thumbnail>http://global.fncstatic.com/static/managed/img/fb2/feeds/Reuters/2013/04/30/2013-04-30T061424Z_1_CBRE93T0HC700_3_HUL-INDIA-RESULTS.JPG</media:thumbnail>
</item>
</channel>
</rss>
